Monarch Therapeutics, SNAP Biosciences enter licensing agreement
Licensing Agreement: SNAP Biosciences and Monarch Therapeutics have entered into a licensing agreement to develop and commercialize the Snap-Car NK cell therapy platform in oncology, utilizing Monarch's small molecule adaptor technology.
Enhanced Technology: This collaboration enhances the functionality of SNAP's universal CAR-based receptor platform, allowing for greater precision and flexibility in therapeutic applications, while Monarch will receive upfront payments and royalties from future sales.
Trade with 70% Backtested Accuracy
Analyst Views on COEP
About COEP
About the author
Coeptis Merger with Z Squared Receives Nasdaq Approval
- Merger Progress: Coeptis Therapeutics Holdings, Inc. announced that Nasdaq has approved its merger with Z Squared, Inc., expected to close in Q2 2026, marking the company's rebranding to Z Squared Inc. and listing on the Nasdaq Global Market, which enhances market recognition and investor confidence.
- Listing Approval: The approval of the listing application is based on shareholder approval of the merger proposals at the January 30, 2026 stockholders' meeting, indicating that the company has met key closing conditions in the merger process, thereby laying the groundwork for subsequent business integration.
- Mining Expansion Plans: Post-merger, Z Squared plans to deploy 9,800 ASIC miners across North Carolina, South Carolina, and Iowa, making it the largest publicly traded Dogecoin miner in the U.S., which is expected to significantly enhance the company's market share and profitability.
- Technology and Operational Enhancements: Coeptis's newly established Technology Division focuses on enhancing operational capabilities through advanced technologies, and combined with Z Squared's digital infrastructure, is anticipated to drive innovation and efficiency in both biopharmaceutical and cryptocurrency sectors, strengthening long-term competitiveness.
COEPTIS CONFIRMS APPROVAL OF Z SQUARED INC.'S APPLICATION FOR NASDAQ LISTING
- Approval Announcement: COEPTIS has announced the approval of ZSQUARED INC.'s application for listing on NASDAQ.
- Significance of Listing: This approval marks a significant milestone for ZSQUARED INC., potentially enhancing its visibility and access to capital in the financial markets.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Coeptis Therapeutics Secures SEC Approval for Merger with Z Squared Inc.
- Merger Progress: Coeptis Therapeutics announced that its registration statement for the merger with Z Squared has been approved by the SEC, marking a significant step forward that is expected to enhance the company's market competitiveness.
- Shareholder Meeting Arrangement: The company will hold a special shareholder meeting on January 30, 2026, to discuss the merger, with the proxy statement and prospectus being mailed to shareholders on January 7, ensuring transparency and shareholder engagement.
- Listing Application Update: The combined company has applied for a Nasdaq listing, and while approval is pending, this move indicates the company's proactive approach to future capital markets, which, if successful, will enhance its market recognition.
- Technology and Business Integration: By merging with Z Squared, Coeptis aims to integrate its biopharmaceutical technologies with cryptocurrency mining operations, driving innovation and diversification to bolster long-term growth potential.
SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes BFIN, COEP, ARIS, CIO for Shareholder Interests
Investigation of Companies: Halper Sadeh LLC is investigating BankFinancial Corporation, Coeptis Therapeutics Holdings, Aris Water Solutions, and City Office REIT for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions.
Legal Rights for Shareholders: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, with the firm offering services on a contingent fee basis, meaning no upfront costs for legal fees.
URGENT: M&A Class Action Firm Ongoing Investigation into the Merger Involving BFIN, ARIS, CIO, and COEP
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
Ongoing Investigations: The firm is currently investigating several companies, including BankFinancial Corporation, Aris Water Solutions, City Office REIT, and Coeptis Therapeutics, regarding their proposed mergers and sales, with shareholder votes scheduled for October 2025.
Coeptis Merger with Z Squared Receives Nasdaq Approval
- Merger Progress: Coeptis Therapeutics Holdings, Inc. announced that Nasdaq has approved its merger with Z Squared, Inc., expected to close in Q2 2026, marking the company's rebranding to Z Squared Inc. and listing on the Nasdaq Global Market, which enhances market recognition and investor confidence.
- Listing Approval: The approval of the listing application is based on shareholder approval of the merger proposals at the January 30, 2026 stockholders' meeting, indicating that the company has met key closing conditions in the merger process, thereby laying the groundwork for subsequent business integration.
- Mining Expansion Plans: Post-merger, Z Squared plans to deploy 9,800 ASIC miners across North Carolina, South Carolina, and Iowa, making it the largest publicly traded Dogecoin miner in the U.S., which is expected to significantly enhance the company's market share and profitability.
- Technology and Operational Enhancements: Coeptis's newly established Technology Division focuses on enhancing operational capabilities through advanced technologies, and combined with Z Squared's digital infrastructure, is anticipated to drive innovation and efficiency in both biopharmaceutical and cryptocurrency sectors, strengthening long-term competitiveness.
COEPTIS CONFIRMS APPROVAL OF Z SQUARED INC.'S APPLICATION FOR NASDAQ LISTING
- Approval Announcement: COEPTIS has announced the approval of ZSQUARED INC.'s application for listing on NASDAQ.
- Significance of Listing: This approval marks a significant milestone for ZSQUARED INC., potentially enhancing its visibility and access to capital in the financial markets.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Coeptis Therapeutics Secures SEC Approval for Merger with Z Squared Inc.
- Merger Progress: Coeptis Therapeutics announced that its registration statement for the merger with Z Squared has been approved by the SEC, marking a significant step forward that is expected to enhance the company's market competitiveness.
- Shareholder Meeting Arrangement: The company will hold a special shareholder meeting on January 30, 2026, to discuss the merger, with the proxy statement and prospectus being mailed to shareholders on January 7, ensuring transparency and shareholder engagement.
- Listing Application Update: The combined company has applied for a Nasdaq listing, and while approval is pending, this move indicates the company's proactive approach to future capital markets, which, if successful, will enhance its market recognition.
- Technology and Business Integration: By merging with Z Squared, Coeptis aims to integrate its biopharmaceutical technologies with cryptocurrency mining operations, driving innovation and diversification to bolster long-term growth potential.
SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes BFIN, COEP, ARIS, CIO for Shareholder Interests
Investigation of Companies: Halper Sadeh LLC is investigating BankFinancial Corporation, Coeptis Therapeutics Holdings, Aris Water Solutions, and City Office REIT for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions.
Legal Rights for Shareholders: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, with the firm offering services on a contingent fee basis, meaning no upfront costs for legal fees.
URGENT: M&A Class Action Firm Ongoing Investigation into the Merger Involving BFIN, ARIS, CIO, and COEP
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
Ongoing Investigations: The firm is currently investigating several companies, including BankFinancial Corporation, Aris Water Solutions, City Office REIT, and Coeptis Therapeutics, regarding their proposed mergers and sales, with shareholder votes scheduled for October 2025.
